Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

Pharma's 2 Biggest Setbacks in 2018
Motley Fool
Sun, 07/1/18 - 11:29 am
Tags:
AbbVie, Celgene, Rova-T, ozanimod
AbbVie, AndroGel partner owe $448 million in antitrust case - U.S. judge
Yahoo/Reuters
Fri, 06/29/18 - 09:26 pm
Tags:
AbbVie, Androgel, generics, antitrust
Galapagos shares are tumbling following disappointing results from a cystic fibrosis trial.
Motley Fool
Fri, 06/29/18 - 11:17 am
Tags:
Galapagos, AbbVie, cystic fibrosis, Vertex Pharmaceuticals, GLPG2737
Argenx Receives Milestone Payment from AbbVie for Preclinical Oncology Drug
CP Wire
Thu, 06/28/18 - 10:10 am
Tags:
Argenx, AbbVie, ARGX-115, cancer
3 Biotech Stocks With Major Potential Catalysts in July
Yahoo/Motley Fool
Wed, 06/27/18 - 09:45 am
Tags:
Neurocrine Biosciences, AbbVie, Progenics, INSYS Therapeutics, Elagolix, endometriosis, Azedra, adrenal tumors, Syndros
AbbVie shares rise on $1 bln investment in partnership with Alphabet-backed health company
Marketwatch
Tue, 06/26/18 - 10:09 am
Tags:
AbbVie, Calico Life Sciences, Alphabet, drug development
After Rova-T bust, AbbVie plans new solid tumor assault, licensing next-gen CAR-T tech from Calibr
Endpoints
Mon, 06/25/18 - 12:45 pm
Tags:
AbbVie, Rova-T, solid tumors, Calibr, CAR-T
Why is AbbVie’s tax rate so low? Humira patents cached in Bermuda: Reuters
Fierce Pharma
Wed, 06/20/18 - 07:10 pm
Tags:
AbbVie, taxes, Bermuda, Humira, patents
5 Experimental New Drugs That Could Be Worth $47 Billion
Motley Fool
Wed, 06/20/18 - 09:26 am
Tags:
GSK2857916, GSK, brolucizumab, Novartis, aducanumab, Biogen, upadacatinib, AbbVie, VX-659 + tezacaftor + ivacaftor, Vertex Pharmaceuticals
Bristol-Myers, AbbVie eye new use for myeloma drug Empliciti after phase 2 combo win
Fierce Pharma
Mon, 06/18/18 - 09:47 pm
Tags:
Bristol-Myers Squibb, AbbVie, Empliciti, Multiple Myeloma
Humira's Sales Will Decline -- and It's Fantastic News for AbbVie
Motley Fool
Wed, 06/13/18 - 10:16 am
Tags:
Humira, AbbVie, biosimilars
AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia
Endpoints
Mon, 06/11/18 - 09:17 am
Tags:
AbbVie, Roche, Venclexta, Rituxan, CLL, chronic lymphocytic leukemia
3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate
Yahoo/Motley Fool
Sun, 06/10/18 - 10:59 am
Tags:
AbbVie, Huimra, Upadacitinib, rheumatoid arthritis
AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024
Fierce Pharma
Fri, 06/8/18 - 09:48 am
Tags:
Humira, AbbVie, Keytruda, Merck, Revlimid, Celgene, Opdivo, Bristol-Myers Squibb
AbbVie to submit upadacitinib to FDA after 5th trial win
Fierce Pharma
Wed, 06/6/18 - 11:31 am
Tags:
AbbVie, Upadacitinib, rheumatoid arthritis, FDA, JAK inhibitors
Two drugs in the pipeline representing unique marketing challenges
Medical Marketing and Media
Tue, 06/5/18 - 10:37 pm
Tags:
valrox, Biomarin, hepatitis A, risankizumab, AbbVie, Boehringer Ingelheim, psoriasis
#ASCO18: AbbVie convinces one top analyst that its $6B ‘megablockbuster’ Rova-T is worthless
Endpoints
Tue, 06/5/18 - 12:09 pm
Tags:
AbbVie, Rova-T, ASCO 2018, antibody-drug conjugate
ASCO18: AbbVie blood cancer combo off to a strong start in Phase 2
Biopharma Dive
Mon, 06/4/18 - 09:37 am
Tags:
AbbVie, Imbruvica, Venclexta, chronic lymphocytic leukemia, small lymphocytic lymphoma, ASCO 2018
How Novartis, Insurers Are Taking Wind Out Of AbbVie's Sales
Investors Business Daily
Fri, 06/1/18 - 10:43 pm
Tags:
AbbVie, Novartis, Humira, biosimilars, Europe, CHMP
AbbVie eyes Imbruvica expansion in CLL as Gazyva pairing hits its marks
Fierce Pharma
Thu, 05/24/18 - 05:44 pm
Tags:
AbbVie, Imbruvica, CLL, Gazyva

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.